Patient adherence and what actually drives discontinuation

Discontinuation is rarely a single choice. It is usually the end of a quiet stretch of side effects, uncertainty, and lost confidence that no one saw in time.

What the data shows

A large share of patients stop chronic therapy within the first year. Tolerability and the sense that the treatment is not working are consistent drivers. Both are visible early if anyone is tracking them.

Why visibility helps

When side effects and daily experience are recorded, a struggling patient can be identified before they give up. The clinician can intervene with context instead of finding out after the fact.

A careful claim

Visibility does not guarantee adherence. It does remove the blindness that lets fixable problems end treatment. That is the contribution Titra is built to make.